Pulmonary Function of Tuberculosis Patients in Medication at Dr. Hasan Sadikin General Hospital Bandung 2013–2014
Abstract
Background: Tuberculosis (TB) is a dangerous global disease that already affects millions of people in the world and acts as the second most frequent cause of death in infectious diseases. Tuberculosis mostly attacks the lung and the inflammation process causes lung damage. The lung damage causes a decrease in pulmonary function. There has been no study about tuberculosis patient lung function in the advanced stage of medication.
Methods: This study was conducted from August–October 2014 at DOTS Policlinic of Dr. Hasan Sadikin General Hospital Bandung. The study population was lung TB patients. The inclusion criteria were 1st category lung TB patients with anti-TB drug treatment on intensive phase. The exclusion criteria were extrapulmonary TB patients, patients with lung surgery history, and patients with asthma or chronic obstructive pulmonary disease (COPD). This study used purposive sampling. The subjects were given a spirometry test where the forced expiratory volume 1 second (FEV1), forced vital capacity (FVC), and their ratio were collected and then interpreted.
Results: Among the 60 subjects included in this study, the data showed that 83.4% of the subjects had a decreased pulmonary function consisting of obstructive (6.7%) and restrictive patterns (76.7%).
Conclusions: The majority of pulmonary TB patients treated with 1st category anti-TB drugs during intensive phase have a decrease in pulmonary function and most of them have restrictive pattern of pulmonary function.
Keywords
Full Text:
PDFReferences
WHO. Global tuberculosis report 2013. WHO; 2013.
Trihono. Riset kesehatan dasar 2010. Jakarta: Departemen Kesehatan Republik Indonesia; 2010.
Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM. Fishman’s manual of pulmonary diseases and disorders. 3th ed. Senior RM, Pack AI, editors. New York: McGraw-Hill; 2008. p. 2734.
Menezes AMB, Hallal PC, Perez-Padilla R, Jardim JRB, Muino A, Lopez MV, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J. 2007;30(6):1180–5.
Paspinodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. Chest. 2007;131(6):1817–24.
Chung K, Chen J, Lee C, Wu H, Wang J, Lee L, et al. Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics (Sao Paulo). 2011;66(4):549–56.
Wu P, Cowling BJ, Schooling CM, Wong IOL, Johnston JM, Leung CC, et al. Age-period-cohort analysis of tuberculosis notifications in Hong Kong from 1961 to 2005. Thorax. 2008;63(4):312–6.
Abioye LA, Omotayo MO, Alakija W. Socio-demographic determinants of stigma among patients with pulmonary tuberculosis in Lagos, Nigeria. Afr Health Sci. 2011;11(Suppl 1):S100–4.
Neyrolles O, Murci LQ. Sex inequality in tuberculosis. PLoS Medicine. 2009;6(12):1–5.
Pereira CAdC, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406.
Dheda K, Booth H, Hugget JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in pulmonary tuberculosis. J Infect Dis. 2005;192(7):1201–9.
Baig IM, Saeed W, Khalil KF. Post-tuberculous chronic obstructive pulmonary disease. J Coll Physicians Surg Pak. 2010;20(8):542–4.
Ramos LMM, Sulmonett N, Ferreira CS, Henriques JF, Miranda SSD. Functional profile of patients with tuberculosis sequelae in a university hospital. J Bras Pneumol. 2006;32(1):43–7.
Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–63.
Mannino DM, McBurnie MA, Tan W, Kocabas A, Anto J, Vollmer WM, et al. Restricted spirometry in the burden of lung disease study. Int J Tuberc Lung Dis. 2012;16(10):1405–11.
Pakasi T, Karyadi E, Wibowo Y, Simanjuntak Y, Suratih N, Salean M, et al. Vitamin A deficiency and other factors associated with severe tuberculosis in Timor and Rote Islands, East Nusa Tenggara Province, Indonesia. Eur J Clin Nutr. 2009;63(9):1130–5.
Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):1–18.
Article Metrics
Abstract view : 381 timesPDF - 240 times
This Journal indexed by
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
View My Stats